Physician profile
Daniel D Hyun
NPI 1194726448
$53,230.37
in general payments reported to CMS, 2019-2025
67 companies · $14K in 2025
The $14K reported for 2025 was more than what 91% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,806 · 2020: $3,953 · 2021: $5,013 · 2022: $5,700 · 2023: $4,606 · 2024: $15K · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $15K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $13K · Consulting Fee: $4,370 · Travel and Lodging: $1,051 · Education: $120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $15,092.12 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13,125.00 |
| Consulting Fee | $4,370.00 |
| Travel and Lodging | $1,051.29 |
| Education | $119.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $15,432.77 | 2021-2025 | |
| Ucb, INC. | $8,350.16 | 2019-2025 | Briviact, Fintepla, Nayzilam |
| Acadia Pharmaceuticals INC | $2,576.42 | 2019-2025 | Nuplazid, Daybue |
| Teva Pharmaceuticals USA, INC. | $2,464.20 | 2019-2025 | Austedo Xr, Austedo, Austedo Xr |
| Neurocrine Biosciences, INC. | $1,790.13 | 2019-2025 | Ingrezza, Ongentys |
| Amgen INC. | $1,525.99 | 2019-2023 | Aimovig |
| Mdd US Operations, LLC | $1,391.50 | 2019-2025 | Gocovri, Gocovri |
| Novartis Pharmaceuticals Corporation | $1,373.82 | 2019-2025 | |
| Kyowa Kirin, INC. | $1,245.26 | 2019-2025 | Nourianz |
| Amneal Pharmaceuticals LLC | $1,195.52 | 2019-2025 | Rytary, Crexont, Ongentys 50mg Capsules 30 |
| Lilly USA, LLC | $1,111.49 | 2019-2025 | Kisunla, Amyvid, Emgality |
| Pfizer INC. | $1,079.76 | 2019-2025 | |
| Acorda Therapeutics, INC | $921.41 | 2019-2024 | Ampyra, Inbrija |
| Emd Serono, INC. | $889.97 | 2019-2025 | Mavenclad, Mavenclad |
| Sk Life Science, INC. | $881.96 | 2020-2025 |
Show all 67 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $747.68 | 2019-2022 | |
| Eisai INC. | $743.15 | 2019-2025 | |
| Biogen, INC. | $694.29 | 2019-2025 | Vumerity, Tysabri, Leqembi |
| Jazz Pharmaceuticals INC. | $661.15 | 2019-2025 | |
| Allergan, INC. | $610.87 | 2019-2022 | |
| Lundbeck LLC | $588.98 | 2019-2025 | Vyepti, Rexulti |
| Tg Therapeutics, INC. | $565.67 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $506.41 | 2019-2024 | Ultomiris |
| Ge Healthcare | $476.08 | 2019-2025 | |
| Biohaven Pharmaceutical Holding Company LTD. | $386.64 | 2022 | |
| Supernus Pharmaceuticals, INC. | $375.73 | 2019-2025 | Qelbree |
| Sumitomo Pharma America, INC. | $316.73 | 2023-2024 | Aptiom |
| Argenx US, INC. | $307.59 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Otsuka America Pharmaceutical, INC. | $305.48 | 2023-2025 | Rexulti, Nuedexta |
| Averitas Pharma INC. | $264.48 | 2023-2025 | Qutenza |
| Avanir Pharmaceuticals, INC. | $242.29 | 2019-2021 | |
| Adamas Pharmaceuticals, INC. | $230.45 | 2019-2021 | |
| Upsher-Smith Laboratories LLC | $208.58 | 2019-2021 | |
| Avion Pharmaceuticals | $171.94 | 2021-2023 | Dhivy |
| Biohaven Pharmaceuticals, INC. | $168.24 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $163.39 | 2020-2022 | |
| Impel Pharmaceuticals INC. | $156.81 | 2022-2023 | Trudhesa |
| Catalyst Pharmaceuticals, INC. | $153.24 | 2023-2025 | Fycompa |
| Greenwich Biosciences, INC. | $151.20 | 2019-2021 | |
| Genentech USA, INC. | $143.37 | 2020-2025 | Ocrevus Zunovo, Ocrevus, Enspryng |
| Medtronic, INC. | $143.16 | 2021-2025 | Percept PC Brainsense, Sensight |
| Merz Pharmaceuticals, LLC | $141.63 | 2025 | Ampyra, Inbrija, Xeomin |
| Livanova USA, INC. | $135.92 | 2019-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Neurelis, INC. | $129.11 | 2022-2024 | Valtoco |
| Grt US Holding, INC. | $98.49 | 2021-2022 | |
| Abbott Laboratories | $98.14 | 2019-2024 | Infinity |
| Celgene Corporation | $95.42 | 2022-2025 | Zeposia |
| Genzyme Corporation | $90.62 | 2019-2023 | |
| Janssen Pharmaceuticals, INC | $83.36 | 2021-2022 | |
| Alnylam Pharmaceuticals INC. | $79.88 | 2021-2023 | Onpattro |
| Nevro Corp. | $77.79 | 2019-2022 | |
| Arbor Pharmaceuticals, INC. | $77.76 | 2019-2021 | |
| Corium, LLC | $71.48 | 2022-2023 | Adlarity |
| Azurity Pharmaceuticals, INC. | $54.63 | 2023-2024 | Horizant, Horizant |
| Axsome Therapeutics, INC. | $37.65 | 2025 | Symbravo, Auvelity |
| Impel Pharmaceuticals LLC | $37.15 | 2025 | Trudhesa |
| Insightec,INC | $30.74 | 2024 | Exablate |
| Vanda Pharmaceuticals INC. | $23.69 | 2021 | |
| Aquestive Therapeutics, INC. | $21.82 | 2021 | |
| Scilex Pharmaceuticals INC. | $21.60 | 2023 | Ztlido |
| Zogenix INC. | $21.04 | 2021 | |
| Aprecia Pharmaceuticals, LLC | $18.20 | 2023 | Spritam |
| Vertical Pharmaceuticals, LLC | $16.87 | 2019 | |
| Sanofi-Aventis U.S. LLC | $16.69 | 2021 | |
| Currax Pharmaceuticals LLC | $14.60 | 2024 | Onzetra Xsail |
| Assertio Therapeutics, INC. | $11.10 | 2020 | |
| Medtronic USA, INC. | $11.03 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Hyun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.